Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Precision medicine stories

Oct 27, 2026

Asciminib shows stronger suppression of leukemia protein than existing treatments in new study

A study led by Adelaide University and SAHMRI provides the first direct evidence that asciminib, a targeted therapy for chronic myeloid leukemia, can rapidly and consistently suppress the cancer-driving protein within one week, offering a more effective and better-tolerated treatment option for CML patients.

Oct 27, 2026·2 sources
00

Mayo Clinic study finds cerebrospinal fluid liquid biopsy detects brain tumor DNA

A Mayo Clinic study published in the Journal of Neuro-Oncology demonstrates that analyzing DNA in cerebrospinal fluid can provide diagnostic information for brain tumors when MRI imaging is unclear or tissue biopsy is difficult or unsafe to obtain.

Oct 27, 2026·2 sources
00

GradientScreen lab-on-chip technology predicts childhood leukemia treatment response

Researchers have developed a gradient-driven microfluidic lab-on-chip platform called GradientScreen that can predict which drug combinations will be most effective for treating pediatric acute lymphoblastic leukemia. The technology screens ratiometric drug combinations to enable precision oncology approaches for the disease, which affects more than 3,500 children annually in the U.S.

Oct 27, 2026·3 sources
00
Oct 26, 2026

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00
Oct 23, 2026

Diagnostic test could help doctors refine prostate cancer treatment with abiraterone

A novel diagnostic test could enable doctors to identify which prostate cancer patients would benefit from more intensive treatment with drugs like abiraterone, while sparing others from unnecessary side effects. The test aims to address the challenge of tailoring treatment for prostate cancer, which affects over 1 million men worldwide and behaves differently in each patient.

Oct 23, 2026·5 sources
00
Oct 20, 2026

Australian researchers develop prime editing platform to give doctors control over cell therapies

A clinician-led research team at WEHI has developed a gene-editing platform using prime editing technology that could allow doctors to have more precise control over cell therapies for patients with complex immune conditions.

Oct 20, 2026·1 source
00
Oct 19, 2026

FDA grants accelerated approval to dostarlimab for dMMR rectal cancer

The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.

Oct 19, 2026·4 sources
00
Oct 6, 2026

Rapid whole genome sequencing reduces pediatric cancer diagnosis time from weeks to days

Researchers have developed a rapid whole genome sequencing workflow for childhood cancer patients that significantly reduces turnaround time through streamlined bioinformatics, demonstrating the feasibility of faster clinical genomic analysis. The advancement builds on established evidence that whole genome sequencing provides important diagnostic benefits for pediatric cancer patients.

Oct 6, 2026·2 sources
00
Sep 23, 2026

FDA approves Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 alterations

The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.

Sep 23, 2026·2 sources
00
Sep 21, 2026

Mayo Clinic and Thermo Fisher partner to create biomedical database company Precure

Mayo Clinic and Thermo Fisher Scientific are forming a new company called Precure to generate population-scale molecular data that will inform the development of diagnostics, therapies, and other healthcare products.

Sep 21, 2026·1 source
00

Imlunestrant combination approved for ESR1-mutated breast cancer

Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.

Sep 21, 2026·1 source
00
Sep 17, 2026

Rare inherited EGFR mutation linked to 25-fold increased lung cancer risk in nonsmokers

Researchers at Dana-Farber Cancer Institute and 23andMe Research Institute have identified a rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene that increases lung cancer risk by 25-fold, helping explain why 10-20% of U.S. lung cancer cases occur in people who never smoked.

Sep 17, 2026·4 sources
00
Sep 12, 2026

FDA expands approval for sevabertinib to frontline treatment of HER2-mutant advanced NSCLC

The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.

Sep 12, 2026·1 source
00
Aug 25, 2026

McKesson acquires Precision Medicine Group for $2.25 billion

Drug distributor McKesson agreed to buy privately held Precision Medicine Group in a $2.25 billion deal, continuing its multi-year strategy to strengthen higher-growth clinical research capabilities.

Aug 25, 2026·2 sources
00
Aug 10, 2026

Spatial transcriptomics reveals molecular programs linked to heart-transplant rejection

Researchers at Vanderbilt Health have published findings in Nature Cardiovascular Research showing that spatial transcriptomics of cardiac biopsies reveals significant cellular and molecular variation in transplant rejection that is not captured by conventional biopsy grading, potentially enabling precision medicine approaches to organ rejection treatment.

Aug 10, 2026·4 sources
00
Aug 6, 2026

Research Advances Understanding of Gene Mutations in Bone Marrow Disorders and Blood Cancers

New studies identify genetic mutations underlying inherited bone marrow failure syndromes and demonstrate that non-driver mutations in myeloproliferative neoplasms like essential thrombocythemia and polycythemia vera have predictive value for patient outcomes.

Aug 6, 2026·3 sources
00
Aug 2, 2026

FDA expands Pluvicto approval for earlier-stage metastatic prostate cancer treatment

The FDA has approved Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with hormone therapy for patients with PSMA-positive metastatic prostate cancer who are still hormone-sensitive, nearly doubling the eligible patient population from its previous indication for hormone-resistant cases.

Aug 2, 2026·8 sources
00
Jul 24, 2026

Study Identifies Germline Variants Linked to Yescarta CAR-T Toxicity and Expansion

New research analyzing patients from Kite Pharma's Yescarta clinical trials has identified inherited genetic signatures that can predict which patients are at higher risk for toxic side effects from CAR-T cell therapy, potentially enabling better patient selection and monitoring for this cancer immunotherapy.

Jul 24, 2026·4 sources
00
Jul 23, 2026

Dassault Systèmes to acquire ArisGlobal for up to $2 billion

Dassault Systèmes agreed to buy drug trial software maker ArisGlobal for as much as $2 billion as the French firm expands its push into life sciences and AI-powered precision medicine.

Jul 23, 2026·2 sources
00

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.

Jul 23, 2026·9 sources
00
Jul 9, 2026

ARPA-H Launches $160 Million Gene Editing Drug Development Program

The Advanced Research Projects Agency for Health (ARPA-H) has launched a $160 million initiative to fund seven groups over five years to develop custom gene editing drugs, aiming to replicate successes like the Baby KJ case.

Jul 9, 2026·1 source
00
Jun 30, 2026

FDA Approves Orca Bio's TREGZI as First Precision-Engineered Cell Therapy for Blood Cancer Transplants

The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.

Jun 30, 2026·7 sources
00
May 30, 2026

DNA Test Could Allow Millions of Breast Cancer Patients to Safely Avoid Chemotherapy

Scientists have developed a DNA test that can distinguish between breast cancer patients who are likely to benefit from chemotherapy and those who can safely avoid it, potentially sparing millions from unnecessary treatment.

May 30, 2026·1 source
00
May 3, 2026

Experimental KRAS G12D Cancer Drug Shows Tumor Shrinkage in First-in-Human Trial

Setidegrasib, an investigational targeted therapy drug, demonstrated ability to slow cancer growth and shrink tumors in a first-in-human clinical trial published in the New England Journal of Medicine, targeting a previously difficult-to-treat cancer mutation.

May 3, 2026·1 source
00
Apr 22, 2026

Revolution Medicines Presents Additional Strong Data on KRAS-Targeting Pancreatic Cancer Drug

Revolution Medicines presented new positive clinical trial data at AACR for its KRAS-targeting drug in pancreatic cancer patients, building on previously reported breakthrough survival results and expanding evidence for a novel class of treatments beyond current KRAS inhibitors.

Apr 22, 2026·3 sources
00

Top claims

  • ▪Adelaide University researchers noted that secondary patient factors beyond specific genetic mutations may still influence chronic myeloid leukemia treatment outcomes.
  • ▪The new measurement method allows doctors to determine earlier if a chronic myeloid leukemia patient is responding well to asciminib treatment.
  • ▪Adelaide University and SAHMRI researchers developed a new measurement method to assess how effectively therapies switch off the cancer-driving BCR::ABL1 protein inside chronic myeloid leukemia patients' blood cells.

Subtopics

Drug Policy, Pricing & Approval15Cancer & Oncology14Drug Approval and Clinical Trials14Cancer treatment11Cancer Treatment & Therapies5Cancer Types5FDA drug approval5Clinical trials4Cancer diagnosis3Cancer research3Cancer treatment breakthroughs3Oncology3Targeted cancer therapy3Biomedical research2Cancer and Cancer Treatment2Diagnostic medicine2Drug development2Hematology & Blood Cancers2Personalized medicine2Pharma2AI in healthcare1Biomedical engineering1Biotech innovation1Cancer immunotherapy1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories